Long-term (1 year) safety and efficacy of methylphenidate modified-release long-acting formulation (MPH-LA) in adults with attention-deficit hyperactivity disorder: a 26-week, flexible-dose, open-label extension to a 40-week, double-blind, randomised, placebo-controlled core study.

Ginsberg, Y; Arngrim, T; Philipsen, A; Gandhi, P; Chen, C-W; Kumar, V; Huss, M

Ginsberg, Y; Arngrim, T; Philipsen, A; Gandhi, P; Chen, C-W; Kumar, V; Huss, M.

Affiliation

Ginsberg Y; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

CNS Drugs ; 28(10): 951-62, 2014 Oct.

Article in En | MEDLINE | ID: mdl-25183661

Subject(s)

Attention Deficit Disorder with Hyperactivity/drug therapy; Methylphenidate/administration & dosage; Psychotropic Drugs/administration & dosage; Adolescent; Adult; Delayed-Action Preparations/administration & dosage; Delayed-Action Preparations/adverse effects; Double-Blind Method; Female; Humans; Male; Methylphenidate/adverse effects; Middle Aged; Psychiatric Status Rating Scales; Psychotropic Drugs/adverse effects; Treatment Outcome; Young Adult

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psychotropic Drugs / Attention Deficit Disorder with Hyperactivity / Methylphenidate Type of study: Clinical_trials Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Journal: CNS Drugs Journal subject: FARMACOLOGIA / NEUROLOGIA / TERAPIA POR MEDICAMENTOS Year: 2014 Type: Article Affiliation country: Sweden

Fulltext

XML

PubMed Links

Search on Google